Concepts (272)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Milk, Human | 41 | 2022 | 139 | 13.210 |
Why?
|
| Infant, Very Low Birth Weight | 37 | 2022 | 141 | 9.440 |
Why?
|
| Intensive Care Units, Neonatal | 38 | 2022 | 152 | 7.780 |
Why?
|
| Breast Feeding | 30 | 2022 | 127 | 6.760 |
Why?
|
| Mothers | 22 | 2022 | 151 | 5.920 |
Why?
|
| Infant, Premature | 37 | 2021 | 164 | 5.130 |
Why?
|
| Infant, Newborn | 59 | 2022 | 522 | 4.690 |
Why?
|
| Enterocolitis, Necrotizing | 13 | 2022 | 32 | 3.180 |
Why?
|
| Lactation | 11 | 2021 | 45 | 2.590 |
Why?
|
| Infant | 26 | 2022 | 483 | 2.450 |
Why?
|
| Infant Nutritional Physiological Phenomena | 14 | 2021 | 56 | 2.390 |
Why?
|
| Milk Banks | 6 | 2020 | 17 | 2.210 |
Why?
|
| Patient Discharge | 8 | 2020 | 137 | 2.060 |
Why?
|
| Enteral Nutrition | 5 | 2022 | 52 | 1.820 |
Why?
|
| Infant, Premature, Diseases | 5 | 2020 | 23 | 1.800 |
Why?
|
| Child Development | 6 | 2020 | 67 | 1.560 |
Why?
|
| Female | 51 | 2022 | 13844 | 1.460 |
Why?
|
| Infant Formula | 4 | 2020 | 18 | 1.460 |
Why?
|
| Intensive Care, Neonatal | 7 | 2020 | 27 | 1.360 |
Why?
|
| Humans | 65 | 2022 | 25178 | 1.320 |
Why?
|
| Breast Milk Expression | 10 | 2020 | 29 | 1.280 |
Why?
|
| Social Support | 3 | 2019 | 168 | 1.230 |
Why?
|
| Gestational Age | 13 | 2020 | 67 | 1.090 |
Why?
|
| Residence Characteristics | 2 | 2019 | 203 | 1.080 |
Why?
|
| Socioeconomic Factors | 3 | 2020 | 276 | 0.930 |
Why?
|
| Infant, Newborn, Diseases | 3 | 2020 | 11 | 0.860 |
Why?
|
| Prospective Studies | 14 | 2021 | 1589 | 0.860 |
Why?
|
| Healthcare Disparities | 2 | 2020 | 79 | 0.850 |
Why?
|
| Health Care Costs | 4 | 2020 | 59 | 0.840 |
Why?
|
| Goals | 3 | 2017 | 36 | 0.810 |
Why?
|
| Bronchopulmonary Dysplasia | 3 | 2016 | 12 | 0.760 |
Why?
|
| Vitamin D | 1 | 2021 | 36 | 0.750 |
Why?
|
| Infant, Low Birth Weight | 2 | 2019 | 14 | 0.740 |
Why?
|
| Neonatology | 1 | 2020 | 3 | 0.720 |
Why?
|
| Birth Weight | 7 | 2022 | 35 | 0.720 |
Why?
|
| Male | 31 | 2021 | 13545 | 0.710 |
Why?
|
| Social Determinants of Health | 1 | 2020 | 30 | 0.710 |
Why?
|
| Gastroschisis | 1 | 2020 | 2 | 0.700 |
Why?
|
| Infant Care | 3 | 2016 | 15 | 0.680 |
Why?
|
| Diet | 3 | 2022 | 164 | 0.680 |
Why?
|
| Child of Impaired Parents | 1 | 2019 | 10 | 0.680 |
Why?
|
| Retrospective Studies | 12 | 2021 | 3105 | 0.660 |
Why?
|
| Pregnancy Complications | 1 | 2019 | 47 | 0.650 |
Why?
|
| Aftercare | 1 | 2018 | 23 | 0.630 |
Why?
|
| Anxiety | 1 | 2019 | 135 | 0.620 |
Why?
|
| Hospitalization | 4 | 2018 | 282 | 0.620 |
Why?
|
| Health Knowledge, Attitudes, Practice | 5 | 2017 | 156 | 0.610 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 67 | 0.590 |
Why?
|
| Oxidative Stress | 1 | 2018 | 100 | 0.590 |
Why?
|
| Nervous System | 1 | 2017 | 9 | 0.580 |
Why?
|
| Stress, Psychological | 1 | 2019 | 206 | 0.580 |
Why?
|
| Maternal Behavior | 1 | 2017 | 10 | 0.570 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2019 | 171 | 0.570 |
Why?
|
| Pregnancy in Adolescence | 1 | 2017 | 12 | 0.570 |
Why?
|
| Educational Status | 5 | 2019 | 279 | 0.540 |
Why?
|
| United States | 6 | 2020 | 1899 | 0.540 |
Why?
|
| Pregnancy | 4 | 2019 | 302 | 0.540 |
Why?
|
| Quality of Health Care | 1 | 2017 | 116 | 0.520 |
Why?
|
| Depression | 1 | 2019 | 395 | 0.520 |
Why?
|
| Informed Consent | 1 | 2015 | 17 | 0.520 |
Why?
|
| Quality Improvement | 1 | 2017 | 143 | 0.510 |
Why?
|
| Sepsis | 2 | 2017 | 133 | 0.510 |
Why?
|
| Bacteria | 1 | 2016 | 70 | 0.510 |
Why?
|
| Gastrointestinal Tract | 1 | 2016 | 50 | 0.510 |
Why?
|
| Mother-Child Relations | 1 | 2015 | 32 | 0.510 |
Why?
|
| Adult | 13 | 2020 | 7087 | 0.490 |
Why?
|
| Decision Making | 1 | 2015 | 219 | 0.440 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2016 | 179 | 0.440 |
Why?
|
| Oxygen | 2 | 2003 | 73 | 0.400 |
Why?
|
| Postpartum Period | 3 | 2021 | 20 | 0.390 |
Why?
|
| Sleep | 2 | 2003 | 272 | 0.340 |
Why?
|
| Nutritive Value | 2 | 2020 | 19 | 0.330 |
Why?
|
| Nutritional Status | 2 | 2020 | 44 | 0.320 |
Why?
|
| Infant, Extremely Low Birth Weight | 3 | 2017 | 17 | 0.320 |
Why?
|
| Models, Biological | 2 | 2009 | 299 | 0.300 |
Why?
|
| Cohort Studies | 8 | 2022 | 1756 | 0.290 |
Why?
|
| Child Language | 2 | 2017 | 10 | 0.280 |
Why?
|
| Age Factors | 2 | 2020 | 720 | 0.280 |
Why?
|
| Incidence | 7 | 2020 | 664 | 0.280 |
Why?
|
| Anti-Bacterial Agents | 2 | 2020 | 326 | 0.270 |
Why?
|
| Qualitative Research | 2 | 2017 | 97 | 0.270 |
Why?
|
| Infant, Extremely Premature | 2 | 2022 | 9 | 0.260 |
Why?
|
| Bottle Feeding | 2 | 2016 | 12 | 0.260 |
Why?
|
| Anthropometry | 1 | 2005 | 33 | 0.260 |
Why?
|
| Bedding and Linens | 2 | 2003 | 4 | 0.250 |
Why?
|
| Carbon Dioxide | 2 | 2003 | 18 | 0.250 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2017 | 280 | 0.240 |
Why?
|
| Child | 5 | 2022 | 1232 | 0.230 |
Why?
|
| Motor Activity | 2 | 2017 | 305 | 0.230 |
Why?
|
| Risk Factors | 4 | 2017 | 2166 | 0.230 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 1299 | 0.230 |
Why?
|
| Prone Position | 1 | 2003 | 31 | 0.210 |
Why?
|
| Tissue Donors | 2 | 2021 | 68 | 0.210 |
Why?
|
| Risk | 2 | 2020 | 195 | 0.210 |
Why?
|
| Maternal Age | 2 | 2019 | 12 | 0.200 |
Why?
|
| Young Adult | 5 | 2019 | 1749 | 0.200 |
Why?
|
| Cost-Benefit Analysis | 2 | 2020 | 119 | 0.200 |
Why?
|
| Evidence-Based Practice | 3 | 2017 | 70 | 0.200 |
Why?
|
| Respiration | 1 | 2001 | 31 | 0.190 |
Why?
|
| Docosahexaenoic Acids | 1 | 2021 | 8 | 0.190 |
Why?
|
| Arachidonic Acid | 1 | 2021 | 12 | 0.190 |
Why?
|
| Directive Counseling | 2 | 2019 | 11 | 0.190 |
Why?
|
| Time Factors | 3 | 2018 | 1327 | 0.180 |
Why?
|
| Dietary Supplements | 1 | 2021 | 52 | 0.180 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2020 | 13 | 0.180 |
Why?
|
| Health Expenditures | 1 | 2020 | 15 | 0.180 |
Why?
|
| Premature Birth | 1 | 2020 | 10 | 0.180 |
Why?
|
| Tissue and Organ Procurement | 2 | 2017 | 26 | 0.180 |
Why?
|
| Academic Medical Centers | 1 | 2021 | 118 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 292 | 0.180 |
Why?
|
| Health Status Disparities | 1 | 2020 | 67 | 0.170 |
Why?
|
| Practice Guidelines as Topic | 3 | 2017 | 277 | 0.170 |
Why?
|
| Linear Models | 2 | 2017 | 231 | 0.170 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 94 | 0.170 |
Why?
|
| Contraception Behavior | 1 | 2019 | 3 | 0.170 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 278 | 0.170 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 174 | 0.170 |
Why?
|
| Logistic Models | 2 | 2017 | 343 | 0.160 |
Why?
|
| Chicago | 3 | 2016 | 782 | 0.160 |
Why?
|
| Nutritional Support | 1 | 2018 | 23 | 0.160 |
Why?
|
| Social Class | 1 | 2019 | 61 | 0.160 |
Why?
|
| Cognition | 2 | 2017 | 1263 | 0.160 |
Why?
|
| Food, Fortified | 1 | 2018 | 4 | 0.160 |
Why?
|
| F2-Isoprostanes | 1 | 2018 | 5 | 0.160 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 832 | 0.150 |
Why?
|
| Length of Stay | 1 | 2020 | 289 | 0.150 |
Why?
|
| Energy Intake | 1 | 2018 | 69 | 0.150 |
Why?
|
| Nod1 Signaling Adaptor Protein | 1 | 2017 | 1 | 0.150 |
Why?
|
| Histamine H2 Antagonists | 1 | 2017 | 5 | 0.150 |
Why?
|
| Protective Factors | 1 | 2017 | 17 | 0.150 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 1621 | 0.150 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2017 | 50 | 0.140 |
Why?
|
| Blood Transfusion | 1 | 2017 | 57 | 0.140 |
Why?
|
| Probiotics | 1 | 2017 | 18 | 0.140 |
Why?
|
| Oligosaccharides | 1 | 2017 | 20 | 0.140 |
Why?
|
| Peer Group | 1 | 2017 | 33 | 0.140 |
Why?
|
| Patient Outcome Assessment | 1 | 2017 | 36 | 0.140 |
Why?
|
| Program Evaluation | 1 | 2017 | 117 | 0.140 |
Why?
|
| Bacteremia | 1 | 2017 | 92 | 0.140 |
Why?
|
| Return to Work | 1 | 2016 | 49 | 0.130 |
Why?
|
| Anemia | 1 | 2017 | 88 | 0.130 |
Why?
|
| DNA, Bacterial | 1 | 2016 | 39 | 0.130 |
Why?
|
| Phylogeny | 1 | 2016 | 44 | 0.130 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2016 | 49 | 0.130 |
Why?
|
| Illinois | 1 | 2016 | 222 | 0.130 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 41 | 0.130 |
Why?
|
| Cost of Illness | 2 | 2013 | 43 | 0.130 |
Why?
|
| Feces | 1 | 2016 | 108 | 0.130 |
Why?
|
| Chondroitinases and Chondroitin Lyases | 1 | 2015 | 5 | 0.130 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2015 | 14 | 0.130 |
Why?
|
| Adolescent | 3 | 2017 | 1998 | 0.130 |
Why?
|
| Interviews as Topic | 1 | 2015 | 113 | 0.130 |
Why?
|
| Cost Savings | 1 | 2015 | 25 | 0.120 |
Why?
|
| Retinopathy of Prematurity | 1 | 2014 | 5 | 0.120 |
Why?
|
| Enterovirus Infections | 1 | 2013 | 1 | 0.110 |
Why?
|
| Diabetes Insipidus, Neurogenic | 1 | 2013 | 2 | 0.110 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2013 | 3 | 0.110 |
Why?
|
| Meningoencephalitis | 1 | 2013 | 5 | 0.110 |
Why?
|
| Postnatal Care | 1 | 2013 | 6 | 0.110 |
Why?
|
| Feeding Methods | 1 | 2013 | 4 | 0.110 |
Why?
|
| Propensity Score | 1 | 2013 | 29 | 0.110 |
Why?
|
| Pharmacopoeias as Topic | 1 | 2012 | 3 | 0.110 |
Why?
|
| Costs and Cost Analysis | 1 | 2013 | 33 | 0.110 |
Why?
|
| Hospital Costs | 1 | 2013 | 58 | 0.100 |
Why?
|
| Pulmonary Gas Exchange | 2 | 2003 | 6 | 0.100 |
Why?
|
| Direct Service Costs | 1 | 2012 | 3 | 0.100 |
Why?
|
| Cardiovascular Agents | 1 | 2012 | 25 | 0.100 |
Why?
|
| Tidal Volume | 2 | 2003 | 11 | 0.100 |
Why?
|
| Pediatrics | 1 | 2012 | 29 | 0.100 |
Why?
|
| Sudden Infant Death | 2 | 2003 | 30 | 0.100 |
Why?
|
| Heart Diseases | 1 | 2012 | 59 | 0.100 |
Why?
|
| Toll-Like Receptor 5 | 1 | 2011 | 1 | 0.100 |
Why?
|
| Codon, Terminator | 1 | 2011 | 2 | 0.100 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2011 | 1 | 0.100 |
Why?
|
| Case-Control Studies | 3 | 2020 | 539 | 0.090 |
Why?
|
| Fluconazole | 1 | 2010 | 7 | 0.090 |
Why?
|
| Cultured Milk Products | 1 | 2009 | 2 | 0.090 |
Why?
|
| Mycoses | 1 | 2010 | 20 | 0.090 |
Why?
|
| Milk | 1 | 2009 | 12 | 0.090 |
Why?
|
| Animals | 5 | 2020 | 3377 | 0.090 |
Why?
|
| Antifungal Agents | 1 | 2010 | 34 | 0.090 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2010 | 30 | 0.090 |
Why?
|
| Pilot Projects | 3 | 2018 | 358 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 438 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2017 | 380 | 0.070 |
Why?
|
| Biomarkers | 2 | 2020 | 537 | 0.070 |
Why?
|
| Ventricular Pressure | 1 | 1996 | 3 | 0.070 |
Why?
|
| Lidocaine | 1 | 1996 | 23 | 0.070 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 1996 | 36 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 2005 | 76 | 0.060 |
Why?
|
| Ion Channel Gating | 1 | 1996 | 183 | 0.060 |
Why?
|
| Blood Gas Analysis | 1 | 2003 | 7 | 0.050 |
Why?
|
| Respiratory Mechanics | 1 | 2003 | 8 | 0.050 |
Why?
|
| Videotape Recording | 1 | 2003 | 28 | 0.050 |
Why?
|
| Respiratory Function Tests | 1 | 2003 | 30 | 0.050 |
Why?
|
| Polysomnography | 1 | 2003 | 67 | 0.050 |
Why?
|
| Face | 1 | 2003 | 21 | 0.050 |
Why?
|
| Air | 1 | 2001 | 4 | 0.050 |
Why?
|
| Methods | 1 | 2001 | 13 | 0.050 |
Why?
|
| Environment | 1 | 2001 | 40 | 0.050 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2001 | 13 | 0.050 |
Why?
|
| Ranibizumab | 1 | 2020 | 1 | 0.050 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2020 | 1 | 0.050 |
Why?
|
| Choroid Diseases | 1 | 2020 | 2 | 0.050 |
Why?
|
| Retinal Diseases | 1 | 2020 | 4 | 0.050 |
Why?
|
| Bevacizumab | 1 | 2020 | 17 | 0.050 |
Why?
|
| Intravitreal Injections | 1 | 2020 | 10 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2020 | 24 | 0.050 |
Why?
|
| Organ Transplantation | 1 | 2001 | 29 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2020 | 62 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2001 | 67 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2021 | 413 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2001 | 119 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2021 | 393 | 0.040 |
Why?
|
| Intention | 1 | 2019 | 21 | 0.040 |
Why?
|
| Obesity | 1 | 2021 | 265 | 0.040 |
Why?
|
| Oceania | 1 | 2018 | 2 | 0.040 |
Why?
|
| Asia | 1 | 2018 | 9 | 0.040 |
Why?
|
| Africa | 1 | 2018 | 8 | 0.040 |
Why?
|
| North America | 1 | 2018 | 35 | 0.040 |
Why?
|
| Europe | 1 | 2018 | 66 | 0.040 |
Why?
|
| North Carolina | 1 | 2018 | 4 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2020 | 306 | 0.040 |
Why?
|
| Internationality | 1 | 2018 | 23 | 0.040 |
Why?
|
| Weight Gain | 1 | 2018 | 61 | 0.040 |
Why?
|
| Income | 1 | 2018 | 70 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2017 | 60 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 124 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2013 | 588 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 243 | 0.030 |
Why?
|
| Phenotype | 1 | 2017 | 283 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2016 | 61 | 0.030 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 1 | 2015 | 12 | 0.030 |
Why?
|
| Macrophage Activation | 1 | 2015 | 9 | 0.030 |
Why?
|
| Biological Availability | 1 | 2015 | 18 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2015 | 91 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2015 | 186 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2001 | 816 | 0.030 |
Why?
|
| Cell Line | 1 | 2015 | 240 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2015 | 72 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2017 | 592 | 0.030 |
Why?
|
| Morbidity | 1 | 2014 | 56 | 0.030 |
Why?
|
| Enterovirus B, Human | 1 | 2013 | 1 | 0.030 |
Why?
|
| Ampicillin | 1 | 2013 | 4 | 0.030 |
Why?
|
| Gentamicins | 1 | 2013 | 14 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 2015 | 187 | 0.030 |
Why?
|
| Inflammation | 1 | 2015 | 253 | 0.030 |
Why?
|
| Organizational Culture | 1 | 2013 | 17 | 0.030 |
Why?
|
| Cardiology | 1 | 2012 | 45 | 0.030 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2011 | 1 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2013 | 122 | 0.020 |
Why?
|
| Disease Management | 1 | 2012 | 108 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2013 | 139 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2011 | 98 | 0.020 |
Why?
|
| Mice | 1 | 2015 | 1197 | 0.020 |
Why?
|
| Heterozygote | 1 | 2011 | 92 | 0.020 |
Why?
|
| Toll-Like Receptors | 1 | 2011 | 17 | 0.020 |
Why?
|
| Cholestasis | 1 | 2010 | 7 | 0.020 |
Why?
|
| Colostrum | 1 | 2010 | 4 | 0.020 |
Why?
|
| Candidiasis | 1 | 2010 | 17 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2011 | 380 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 902 | 0.020 |
Why?
|
| Prognosis | 1 | 2009 | 726 | 0.020 |
Why?
|
| Chick Embryo | 1 | 1996 | 11 | 0.020 |
Why?
|
| Isotonic Solutions | 1 | 1996 | 10 | 0.020 |
Why?
|
| Sodium Channels | 1 | 1996 | 15 | 0.020 |
Why?
|
| Verapamil | 1 | 1996 | 26 | 0.020 |
Why?
|
| Calcium Channel Blockers | 1 | 1996 | 35 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2010 | 3146 | 0.010 |
Why?
|
| Lymphoma | 1 | 2001 | 37 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2001 | 162 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2001 | 175 | 0.010 |
Why?
|